Appletreeclinics Network Sp. z o.o.

Lodz 11 trials 1 recruiting

11 Registered trials

1 Currently recruiting

Organisation

Appletreeclinics Network Sp. z o.o.

Location

Lodz, Poland

Identifier

ORG-100042068

Address

Ul. Ks. Bp. Wincentego Tymienieckiego 20, 90-349, Poland

Departments

Appletreeclinics Ośrodek Badań Klinicznych
Clinical Trial
Dermatology
Gastroenterology
N/A

Clinical trials at this site (11)

Search interface

ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised

2022-500535-36-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
Cytisine for nicotine-containing electronic cigarette and tobacco cigarette cessation: a randomized placebo-controlled trial Recruiting

2023-504708-27-00 electronic cigarette cessation 5 2024-11-02
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 4 2021-12-01
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended

2023-506477-35-00 moderate to severe plaque psoriasis 4 2024-04-02
To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended

2024-511615-16-00 atopic dermatitis 4 2023-08-25
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended

2022-501586-50-00 Atopic Dermatitis 5 2023-05-15
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended

2023-508955-37-00 Moderate to severe atopic dermatitis 5 2018-10-10